Jennifer Doudna
American biochemist and Nobel laureate
Follow Jennifer Doudna on Notably News to receive short updates to your email — rarely!
| 2025 | Awarded the National Medal of Technology and Innovation. |
| 2023 | Received an honorary Doctor of Science degree from Harvard. |
| 2023 | Inducted into the National Inventors Hall of Fame. |
| 2022 | Joined Sixth Street Partners as their chief science advisor, focusing on guiding investment decisions related to CRISPR technology. |
| 2021 | Received the Award for Excellence in Molecular Diagnostics from the Association for Molecular Pathology. Appointed by Pope Francis as a member of the Pontifical Academy of Sciences. |
| 2020 | Mammoth Biosciences successfully raised a series B round of funding, securing $45 million to support its technological development and expansion. |
| 2020 | Awarded the Nobel Prize in Chemistry alongside Emmanuelle Charpentier for the development of CRISPR-Cas9 genome editing technology. |
| March 2020 | Jennifer Doudna initiated a collaborative effort with colleagues at the Innovative Genomics Institute (IGI) to develop CRISPR-based technologies for addressing the COVID-19 pandemic, establishing a testing center to process patient samples. |
| 2019 | Received the Harvey Prize from Technion/Israel and the LUI Che Woo Prize in Welfare Betterment. |
| 2018 | Awarded the NAS Award in Chemical Sciences, the Pearl Meister Greengard Prize, and a Medal of Honor from the American Cancer Society. Received the Kavli Prize in Nanoscience with Charpentier and Šikšnys. Received an honorary Doctor of Science degree from USC. |
| September 2018 | A US appeals court decided in favor of the Broad Institute in the CRISPR patent dispute, ruling against UC Berkeley's claim. |
| 2017 | Awarded the Japan Prize. Received the Golden Plate Award from the American Academy of Achievement. |
| 2017 | Jennifer Doudna co-founded Mammoth Biosciences, a San Francisco-based bioengineering tech startup focused on bio sensing tests across multiple sectors including healthcare, agriculture, and biodefense. |
| 2017 | Doudna co-authored 'A Crack in Creation: Gene Editing and the Unthinkable Power to Control Evolution', a first-person account of the CRISPR scientific breakthrough. |
| 2017 | Awarded the Japan Prize. |
| 2016 | Received the Canada Gairdner International Award with Charpentier, Zhang, Horvath, and Barrangou. Received the Heineken Prize for Biochemistry and Biophysics. Elected as a Foreign Member of the Royal Society. |
| 2016 | Receives the Tang Prize and the Canada Gairdner International Award. |
| 2015 | Receives the Breakthrough Prize in Life Sciences for CRISPR-Cas9 genome editing technology with Emmanuelle Charpentier. Named one of Time's 100 most influential people. |
| 2014 | Elected to the National Academy of Inventors. |
| 2014 | Doudna co-founded the Innovative Genomics Institute and became its founding chair of the governance board, establishing an organization dedicated to advancing genomic research and its applications. |
| June 2014 | Doudna quit Editas Medicine following a contentious experience. |
| September 2013 | Doudna cofounded Editas Medicine with Feng Zhang and others, despite ongoing patent disputes. |
| 2012 | With Emmanuelle Charpentier, proposes that CRISPR-Cas9 could be used for programmable genome editing, a breakthrough considered one of the most significant discoveries in biology. |
| 2011 | Doudna cofounded Caribou Biosciences to commercialize CRISPR technology. |
| 2010 | Elected to the National Academy of Medicine. |
This contents of the box above is based on material from the Wikipedia article Jennifer Doudna, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.